Страна: Ірландія
мова: англійська
Джерело: HPRA (Health Products Regulatory Authority)
CARBAMAZEPINE
Novartis Pharmaceuticals UK Ltd
125 Milligram
Suppositories
1994-04-19
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tegretol 125mg Suppositories 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 125 mg carbamazepine For a full list of excipients, see 6.1. 3 PHARMACEUTICAL FORM Suppository White to off-white, torpedo shaped suppositories with a fatty odour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As an anticonvulsant in the management of epilepsy (generalised tonic-clonic and partial seizures). Tegretol suppositories are for short-term use as replacement therapy in patients where oral treatment is temporarily not possible. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Tegretol is available in suppositories, for short term use. They are intended as replacement therapy (maximum period recommended: 7 days) in patients for whom oral treatment is temporarily not possible, for example in post-operative patients. When switching from oral formulations of Tegretol to suppositories the dosage should be increased by approximately 25% (the 125mg and 250mg suppositories correspond to the 100 and 200mg tablets respectively). The final dose adjustment should always depend on the clinical response in the individual patient. Tegretol suppositories, in appropriate doses, have been shown to provide plasma levels which are well within the therapeutic range. The pharmacokinetic properties of the suppositories are such that the maximum daily dose is limited to 1000mg (250mg four times daily at 6 hourly intervals). _USE IN THE ELDERLY_ Due to the potential for drug interactions, the dosage of Tegretol should be selected with caution in elderly patients. _USE IN PAEDIATRIC PATIENTS_ Tegretol suppositories are not recommended for very young children IRISH MEDICINES BOARD ___________________________________________________________________________ Прочитайте повний документ